pd 153035 has been researched along with Inflammation in 3 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prada, PO | 1 |
| Ropelle, ER | 1 |
| Mourão, RH | 1 |
| de Souza, CT | 1 |
| Pauli, JR | 1 |
| Cintra, DE | 1 |
| Schenka, A | 1 |
| Rocco, SA | 1 |
| Rittner, R | 1 |
| Franchini, KG | 1 |
| Vassallo, J | 1 |
| Velloso, LA | 1 |
| Carvalheira, JB | 1 |
| Saad, MJ | 1 |
| Woodworth, CD | 1 |
| Michael, E | 1 |
| Marker, D | 1 |
| Allen, S | 1 |
| Smith, L | 1 |
| Nees, M | 1 |
| Xue, M | 1 |
| Campbell, D | 1 |
| Jackson, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Histological Characterization and Differentiation of Rash From Other EGFR Inhibitors[NCT00709878] | 32 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00709878)
Timeframe: 6 months
| Intervention | Total number of cases (Number) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ulceration | Parakeratosis | Acanthosis | Epidermal atrophy | Epidermal dysmaturation | Epidermal dyskeratosis | Epidermal neutrophilc infiltrate | Epidermal monocytic infiltrate | Epidermal eosinophilic infiltrate | Dermal neutrophilic infiltrate | Dermal monocytic infiltrate | Dermal eosinophilic infiltrate | Follicular concretions | Follicular neutrophilic pustule | Dysmorphic follicle | Follicular dyskeratosis | Follicular neurtrophilic infiltrate | Follicular monocytic infiltrate | Follicular eosinophilic infiltrate | Eccrine dyskeratosis | Eccrine necrosis | Eccrine infiltrate | Sebaceous infiltrate | |
| Patients Treated With Cetuximab (C) | 1 | 2 | 1 | 5 | 3 | 3 | 1 | 0 | 0 | 0 | 4 | 2 | 5 | 4 | 2 | 3 | 5 | 2 | 1 | 1 | 2 | 0 | 1 |
| Patients Treated With Erlotinib (E) | 2 | 0 | 0 | 4 | 0 | 0 | 1 | 0 | 1 | 4 | 4 | 0 | 3 | 6 | 4 | 1 | 7 | 2 | 1 | 0 | 1 | 0 | 3 |
| Patients Treated With Lapatinib (L) | 1 | 1 | 1 | 7 | 2 | 3 | 1 | 0 | 0 | 2 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | 2 | 2 | 0 | 0 | 0 | 0 |
| Patients Treated With Panitumumab (P) | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 2 | 0 | 2 | 4 | 0 | 2 | 3 | 2 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 1 |
3 other studies available for pd 153035 and Inflammation
| Article | Year |
|---|---|
EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Dietary Fats; Enzyme Inhibitors; ErbB Receptors | 2009 |
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor | 2005 |
Protein C is an autocrine growth factor for human skin keratinocytes.
Topics: Antibodies, Monoclonal; Antigens, CD; Autocrine Communication; Blood Coagulation; Cell Proliferation | 2007 |